TapewireFind a company

person · Reporting owner

POWELL MICHAEL

Disclosed activity across 14 companies

Tapewire entity
39729
SEC CIK
0001202793

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Bicara Therapeutics Inc.BCAX · Entity 4673DirectorJune 09, 2026June 10, 2026
Entasis Therapeutics Holdings Inc.ETTX · Entity 1603610% ownerSeptember 28, 2018October 02, 2018
Galera Therapeutics, Inc.GRTX · Entity 15899DirectorJune 14, 2023June 16, 2023
Ocera Therapeutics, Inc.OCRX · Entity 171193DirectorDecember 31, 2016February 10, 2017
Principia Biopharma Inc.PRNB · Entity 14642310% ownerSeptember 18, 2018September 20, 2018
SYNLOGIC, INC.SYBX · Entity 7801DirectorJune 05, 2019June 07, 2019
Vera Therapeutics, Inc.VERA · Entity 435810% ownerMay 18, 2021May 18, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bicara Therapeutics Inc.

Report date June 09, 2026 · Filed June 10, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.56 · Expires 2036-06-09Direct19,475 Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-09 · Grant · Acquired 19,475 · Balance 19,475

F1: The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.

Entasis Therapeutics Holdings Inc.

Report date September 28, 2018 · Filed October 02, 2018

Jointly reported with Sofinnova Venture Partners IX, L.P., Sofinnova Management IX, L.L.C., HEALY JAMES, Mehra Anand

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect359,267 Reported balance After 2018-09-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2018-09-28 · Conversion · Acquired 359,267 · Balance 359,267

F1: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect842,454 Reported balance After 2018-09-28 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2018-09-28 · Conversion · Acquired 458,425 · Balance 842,454

F1: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3: This number includes an aggregate of 24,762 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.

F2: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect1,180,178 Reported balance After 2018-09-28 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2018-09-28 · Purchase · Acquired 337,724 · Balance 1,180,178

F2: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.

Series B-1 Tranche A Convertible Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-09-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2018-09-28 · Conversion · Disposed 7,446,904 · Balance 0

F1: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.

Series B-1 Tranche B Convertible Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-09-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2018-09-28 · Conversion · Disposed 9,502,249 · Balance 0

F1: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.

F3: This number includes an aggregate of 24,762 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.

Galera Therapeutics, Inc.

Report date June 14, 2023 · Filed June 16, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.27 · Expires 2033-06-13Direct64,000 Reported balance After 2023-06-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-06-14 · Grant · Acquired 64,000 · Balance 64,000

F1: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date.

Ocera Therapeutics, Inc.

Report date December 31, 2016 · Filed February 10, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2016-07-29 transaction · row 1
1 source row

Row 1 · 2016-07-29 · Sale · Disposed 11,969 · Balance 0

F1: These shares were issued upon the Reporting Person's exercise of a stock option on July 11, 2016 that was reported on a Form 4 filed on July 13, 2016. The cash proceeds from this sale of the shares were donated by the Reporting Person to Washington University in St. Louis on August 17, 2016.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were issued upon the Reporting Person's exercise of a stock option on July 11, 2016 that was reported on a Form 4 filed on July 13, 2016. The cash proceeds from this sale of the shares were donated by the Reporting Person to Washington University in St. Louis on August 17, 2016.

Principia Biopharma Inc.

Report date September 18, 2018 · Filed September 20, 2018

Jointly reported with Sofinnova Venture Partners VIII, L.P., Sofinnova Management VIII, L.L.C., HEALY JAMES, Mehra Anand

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,038,208 Last balance in matching sequence After 2018-09-18 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rows

Row 1 · 2018-09-18 · Conversion · Acquired 625,482 · Balance 625,482

F1: Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Row 2 · 2018-09-18 · Conversion · Acquired 521,235 · Balance 1,146,717

F3: Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Row 3 · 2018-09-18 · Conversion · Acquired 453,954 · Balance 1,600,671

F4: Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Row 4 · 2018-09-18 · Conversion · Acquired 167,537 · Balance 1,768,208

F5: Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Row 5 · 2018-09-18 · Purchase · Acquired 270,000 · Balance 2,038,208

F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Series B-1 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-09-18 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2018-09-18 · Conversion · Disposed 625,482 · Balance 0

F1: Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Series B-2 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-09-18 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2018-09-18 · Conversion · Disposed 521,235 · Balance 0

F3: Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Series B-3 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-09-18 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2018-09-18 · Conversion · Disposed 453,954 · Balance 0

F4: Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Series C Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-09-18 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2018-09-18 · Conversion · Disposed 167,537 · Balance 0

F5: Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Expires 2022-12-29Direct20,938 Reported balance Holding disclosure · report date 2018-09-18 · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · Balance 20,938

F6: This warrant has converted from a warrant to purchase Series B-3 Convertible Preferred Stock into a warrant to purchase Common Stock.

F7: This warrant is exercisable at any time.

F4: Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

F3: Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F4: Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F5: Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F6: This warrant has converted from a warrant to purchase Series B-3 Convertible Preferred Stock into a warrant to purchase Common Stock.

F7: This warrant is exercisable at any time.

SYNLOGIC, INC.

Report date June 05, 2019 · Filed June 07, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2029-06-05Direct10,000 Reported balance After 2019-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-06-05 · Grant · Acquired 10,000 · Balance 10,000

F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to each non-employee director's continued service as a director of the Corporation.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to each non-employee director's continued service as a director of the Corporation.

Vera Therapeutics, Inc.

Report date May 18, 2021 · Filed May 18, 2021

Jointly reported with Sofinnova Venture Partners X, L.P., Sofinnova Management X, L.P., HEALY JAMES

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect2,914,776 Last balance in matching sequence After 2021-05-18 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2021-05-18 · Conversion · Acquired 2,187,504 · Balance 2,187,504

F1: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Row 2 · 2021-05-18 · Purchase · Acquired 727,272 · Balance 2,914,776

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Series C Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2021-05-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2021-05-18 · Conversion · Disposed 2,187,504 · Balance 0

F1: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the Reporting Persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Past disclosures · reporting ended (7)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Akouos, Inc.

Report date June 30, 2020 · Filed July 01, 2020

Jointly reported with Sofinnova Venture Partners X, L.P., Sofinnova Management X, L.P., HEALY JAMES, Katabi Maha

Section 16 reporting ended · disclosed 2020-07-01. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,515,073 Last balance in matching sequence After 2020-06-30 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 1 · 2020-06-30 · Conversion · Acquired 856,262 · Balance 856,262

F1: Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Row 2 · 2020-06-30 · Conversion · Acquired 599,988 · Balance 1,456,250

F3: Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Row 3 · 2020-06-30 · Purchase · Acquired 58,823 · Balance 1,515,073

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Series A Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-06-30 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2020-06-30 · Conversion · Disposed 18,044,028 · Balance 0

F1: Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Series B Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-06-30 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2020-06-30 · Conversion · Disposed 12,643,557 · Balance 0

F3: Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Upon the closing of the initial public offering of the Issuer's Common Stock, the Series A Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series A Preferred Stock had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

F3: Upon the closing of the initial public offering of the Issuer's Common Stock, the Series B Preferred Stock automatically converted into Common Stock on a 21.073-for-1 basis without payment of further consideration. The shares of Series B Preferred Stock had no expiration date.

Bolt Biotherapeutics, Inc.

Report date February 09, 2021 · Filed February 09, 2021

Jointly reported with Sofinnova Venture Partners X, L.P., Sofinnova Management X, L.P., Katabi Maha

Section 16 reporting ended · disclosed 2021-02-09. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,754,437 Last balance in matching sequence After 2021-02-09 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 1 · 2021-02-09 · Conversion · Acquired 1,104,209 · Balance 1,104,209

F1: The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Row 2 · 2021-02-09 · Conversion · Acquired 1,200,228 · Balance 2,304,437

F3: The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Row 3 · 2021-02-09 · Purchase · Acquired 450,000 · Balance 2,754,437

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Series C-1 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2021-02-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2021-02-09 · Conversion · Disposed 1,104,209 · Balance 0

F1: The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Series C-2 Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2021-02-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2021-02-09 · Conversion · Disposed 1,200,228 · Balance 0

F3: The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series C-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's initial public offering (the "IPO") and had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

F3: The Series C-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1 basis immediately upon closing of the Issuer's IPO and had no expiration date.

Checkmate Pharmaceuticals, Inc.

Report date May 31, 2022 · Filed May 31, 2022

Section 16 reporting ended · disclosed 2022-05-31. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.19 · Expires 2031-08-09Direct0 Reported balance After 2022-05-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-05-31 · Disposition to issuer · Disposed 30,000 · Balance 0

F1: At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.27 · Expires 2031-06-16Direct0 Reported balance After 2022-05-31 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2022-05-31 · Disposition to issuer · Disposed 10,030 · Balance 0

F1: At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.95 · Expires 2030-11-09Direct0 Reported balance After 2022-05-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2022-05-31 · Disposition to issuer · Disposed 30,000 · Balance 0

F1: At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes.

F2: At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable.

Filing footnotes · ownership attribution and instrument terms

F1: At the effective time of the merger contemplated by the Agreement and Plan of Merger dated April 18, 2022, among Checkmate Pharmaceuticals, Inc. (the "Issuer"), Regeneron Pharmaceuticals, and Scandinavian Acquisition Sub, Inc. (the "Merger"), each option granted by the Issuer to purchase Issuer Common Stock, whether or not vested, which has a per share exercise price that is less than $10.50 (each, an "In the Money Issuer Option") that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the total number of Issuer Common Stock subject to such In the Money Issuer Option and (2) the excess of $10.50 over the exercise price of such In the Money Issuer Option, subject to any required withholding of taxes.

F2: At the effective time of the Merger, each option granted by the Issuer to purchase Issuer Common Stock which has a per share exercise price greater than or equal to $10.50 that was outstanding and unexercised as of immediately prior to the effective time of the Merger was cancelled with no consideration payable.

Inozyme Pharma, Inc.

Report date July 28, 2020 · Filed July 28, 2020

Jointly reported with Sofinnova Venture Partners X, L.P., Sofinnova Management X, L.P., HEALY JAMES, Katabi Maha

Section 16 reporting ended · disclosed 2020-07-28. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,028,308 Last balance in matching sequence After 2020-07-28 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2020-07-28 · Conversion · Acquired 1,590,808 · Balance 1,590,808

F1: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Row 2 · 2020-07-28 · Purchase · Acquired 437,500 · Balance 2,028,308

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-07-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2020-07-28 · Conversion · Disposed 11,888,112 · Balance 0

F1: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: The shares are held directly by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP X. James I. Healy, Maha Katabi, and Michael F. Powell are the managing members of SM X and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP X. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Iterum Therapeutics plc

Report date June 01, 2020 · Filed June 03, 2020

Jointly reported with Sofinnova Venture Partners IX, L.P., Sofinnova Management IX, L.L.C., HEALY JAMES

Section 16 reporting ended · disclosed 2020-06-03. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect1,226,514 Last balance in matching sequence After 2020-06-02 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2020-06-01 · Sale · Disposed 100,000 · Balance 1,626,514

F1: The price realized by the reporting person from the sales reported in Table I of this Form 4 is less than the market price of the Issuer's Ordinary Shares on the date of any purchase transaction that is potentially matchable during the previous six months. Thus, no short-swing profit is recoverable for purposes of Section 16(b).

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

F3: The securities are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any.

Row 2 · 2020-06-02 · Sale · Disposed 400,000 · Balance 1,226,514

F1: The price realized by the reporting person from the sales reported in Table I of this Form 4 is less than the market price of the Issuer's Ordinary Shares on the date of any purchase transaction that is potentially matchable during the previous six months. Thus, no short-swing profit is recoverable for purposes of Section 16(b).

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.58 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

F3: The securities are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The price realized by the reporting person from the sales reported in Table I of this Form 4 is less than the market price of the Issuer's Ordinary Shares on the date of any purchase transaction that is potentially matchable during the previous six months. Thus, no short-swing profit is recoverable for purposes of Section 16(b).

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

F3: The securities are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the securities held by the Fund. Dr. James I. Healy and Michael F. Powell, Ph.D. are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by the Fund. Each reporting person disclaims beneficial ownership of such securities, except to the extent of his or its proportionate pecuniary interest therein, if any.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.58 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

Section 16 reporting ended · disclosed 2016-10-24. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote1,134,851 Reported balance After 2016-10-20 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2016-10-20 · Sale · Disposed 724,788 · Balance 1,134,851

F1: Shares are held by Sofinnova Venture Partners VI, L.P. ("SVP VI"). Sofinnova Management VI, L.L.C. ("SM VI") is the general partner of SVP VI and James I. Healy ("Healy"), Michael F. Powell ("Powell"), Alain L. Azan ("Azan") and Eric P. Buatois ("Buatois"), the managing members of SM VI, and Anand Mehra ("Mehra"), a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities.

Common StockSEC Table I · non-derivativeIndirectSee footnote224,845 Reported balance After 2016-10-20 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2016-10-20 · Sale · Disposed 13,367 · Balance 224,845

F2: Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG ("SVP KG"). SM VI is the managing limited partner of SVP KG, and Healy, Powell, Azan and Buatois, the managing members of SM VI, and Mehra, a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities.

Common StockSEC Table I · non-derivativeIndirectSee footnote15,470 Reported balance After 2016-10-20 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2016-10-20 · Sale · Disposed 12,528 · Balance 15,470

F3: Shares are held by Sofinnova Venture Affiliates VI, L.P. ("SVA VI"). SM VI is the general partner of SVA VI, and Healy, Powell, Azan and Buatois, the managing members of SM VI, and Mehra, a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities.

Filing footnotes · ownership attribution and instrument terms

F1: Shares are held by Sofinnova Venture Partners VI, L.P. ("SVP VI"). Sofinnova Management VI, L.L.C. ("SM VI") is the general partner of SVP VI and James I. Healy ("Healy"), Michael F. Powell ("Powell"), Alain L. Azan ("Azan") and Eric P. Buatois ("Buatois"), the managing members of SM VI, and Anand Mehra ("Mehra"), a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities.

F2: Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG ("SVP KG"). SM VI is the managing limited partner of SVP KG, and Healy, Powell, Azan and Buatois, the managing members of SM VI, and Mehra, a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities.

F3: Shares are held by Sofinnova Venture Affiliates VI, L.P. ("SVA VI"). SM VI is the general partner of SVA VI, and Healy, Powell, Azan and Buatois, the managing members of SM VI, and Mehra, a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities.

NextCure, Inc.

Report date November 15, 2019 · Filed November 19, 2019

Jointly reported with Sofinnova Venture Partners IX, L.P., Sofinnova Management IX, L.L.C., HEALY JAMES, Mehra Anand

Section 16 reporting ended · disclosed 2019-11-19. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,671,856 Reported balance After 2019-11-15 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2019-11-15 · Purchase · Acquired 150,000 · Balance 2,671,856

F1: The shares are held directly by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held directly by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 13, 2019 Filed May 15, 2019 17:59 UTC NextCure, Inc. NXTC · Entity 7461 ConversionCommon Stock 464,599 Not disclosed Not disclosed
Disclosure

SEC source: 0001144204-19-026681 · tv521648_4.xml · nonDerivative · entry 2

Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner

Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 743,358

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.direct: The shares are held directly by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Read SEC document
May 13, 2019 Filed May 15, 2019 17:59 UTC NextCure, Inc. NXTC · Entity 7461 ConversionCommon Stock 278,759 Not disclosed Not disclosed
Disclosure

SEC source: 0001144204-19-026681 · tv521648_4.xml · nonDerivative · entry 1

Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner

Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,759

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date.

F2 · ownership.direct: The shares are held directly by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.

Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:41 UTC Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 ConversionSeries B-1 Tranche B Convertible Preferred Stock · Derivative 9,502,249 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-053539 · doc4.xml · derivative · entry 5

Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner

Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 458,425 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.underlying_shares: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.

Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:41 UTC Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 ConversionSeries B-1 Tranche A Convertible Preferred Stock · Derivative 7,446,904 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-053539 · doc4.xml · derivative · entry 4

Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner

Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 359,267 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.underlying_shares: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.

Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:41 UTC Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 PurchaseCommon Stock 337,724 $15.00 $5,065,860.00
Disclosure

SEC source: 0001209191-18-053539 · doc4.xml · nonDerivative · entry 3

Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner

Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,180,178

F2 · ownership.direct: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.

Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:41 UTC Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 ConversionCommon Stock 458,425 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-053539 · doc4.xml · nonDerivative · entry 2

Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner

Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 842,454

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · balance_after: This number includes an aggregate of 24,762 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018.

F2 · ownership.direct: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.

Read SEC document
September 28, 2018 Filed Oct 2, 2018 21:41 UTC Entasis Therapeutics Holdings Inc. ETTX · Entity 16036 ConversionCommon Stock 359,267 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-053539 · doc4.xml · nonDerivative · entry 1

Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner

Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 359,267

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.direct: The reportable shares are held of record by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX. The individual managing members of SM IX are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP IX. Such persons and entities disclaim beneficial ownership over the shares held by SVP IX except to the extent of any pecuniary interest therein.

Read SEC document
September 18, 2018 Filed Sep 20, 2018 19:02 UTC Principia Biopharma Inc. PRNB · Entity 146423 ConversionSeries C Preferred Stock · Derivative 167,537 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-051838 · doc4.xml · derivative · entry 9

Sofinnova Venture Partners VIII, L.P. · CIK 0001524064 · 10% owner

Sofinnova Management VIII, L.L.C. · CIK 0001559565 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 167,537 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F5 · price: Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F5 · derivative.exercise_date: Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F5 · derivative.expiration_date: Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2 · ownership.direct: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Read SEC document
September 18, 2018 Filed Sep 20, 2018 19:02 UTC Principia Biopharma Inc. PRNB · Entity 146423 ConversionSeries B-3 Preferred Stock · Derivative 453,954 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-051838 · doc4.xml · derivative · entry 8

Sofinnova Venture Partners VIII, L.P. · CIK 0001524064 · 10% owner

Sofinnova Management VIII, L.L.C. · CIK 0001559565 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 453,954 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F4 · price: Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F4 · derivative.exercise_date: Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F4 · derivative.expiration_date: Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2 · ownership.direct: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Read SEC document
September 18, 2018 Filed Sep 20, 2018 19:02 UTC Principia Biopharma Inc. PRNB · Entity 146423 ConversionSeries B-2 Preferred Stock · Derivative 521,235 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-051838 · doc4.xml · derivative · entry 7

Sofinnova Venture Partners VIII, L.P. · CIK 0001524064 · 10% owner

Sofinnova Management VIII, L.L.C. · CIK 0001559565 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 521,235 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F3 · price: Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F3 · derivative.exercise_date: Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F3 · derivative.expiration_date: Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2 · ownership.direct: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Read SEC document
September 18, 2018 Filed Sep 20, 2018 19:02 UTC Principia Biopharma Inc. PRNB · Entity 146423 ConversionSeries B-1 Preferred Stock · Derivative 625,482 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-051838 · doc4.xml · derivative · entry 6

Sofinnova Venture Partners VIII, L.P. · CIK 0001524064 · 10% owner

Sofinnova Management VIII, L.L.C. · CIK 0001559565 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 625,482 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F1 · price: Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F1 · derivative.exercise_date: Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F1 · derivative.expiration_date: Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2 · ownership.direct: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Read SEC document
September 18, 2018 Filed Sep 20, 2018 19:02 UTC Principia Biopharma Inc. PRNB · Entity 146423 PurchaseCommon Stock 270,000 $17.00 $4,590,000.00
Disclosure

SEC source: 0001209191-18-051838 · doc4.xml · nonDerivative · entry 5

Sofinnova Venture Partners VIII, L.P. · CIK 0001524064 · 10% owner

Sofinnova Management VIII, L.L.C. · CIK 0001559565 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,038,208

F2 · ownership.direct: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Read SEC document
September 18, 2018 Filed Sep 20, 2018 19:02 UTC Principia Biopharma Inc. PRNB · Entity 146423 ConversionCommon Stock 167,537 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-051838 · doc4.xml · nonDerivative · entry 4

Sofinnova Venture Partners VIII, L.P. · CIK 0001524064 · 10% owner

Sofinnova Management VIII, L.L.C. · CIK 0001559565 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,768,208

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Each share of the Series C Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2 · ownership.direct: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Read SEC document
September 18, 2018 Filed Sep 20, 2018 19:02 UTC Principia Biopharma Inc. PRNB · Entity 146423 ConversionCommon Stock 453,954 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-051838 · doc4.xml · nonDerivative · entry 3

Sofinnova Venture Partners VIII, L.P. · CIK 0001524064 · 10% owner

Sofinnova Management VIII, L.L.C. · CIK 0001559565 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,600,671

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: Each share of the Series B-3 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2 · ownership.direct: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Read SEC document
September 18, 2018 Filed Sep 20, 2018 19:02 UTC Principia Biopharma Inc. PRNB · Entity 146423 ConversionCommon Stock 521,235 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-051838 · doc4.xml · nonDerivative · entry 2

Sofinnova Venture Partners VIII, L.P. · CIK 0001524064 · 10% owner

Sofinnova Management VIII, L.L.C. · CIK 0001559565 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,146,717

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Each share of the Series B-2 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2 · ownership.direct: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Read SEC document
September 18, 2018 Filed Sep 20, 2018 19:02 UTC Principia Biopharma Inc. PRNB · Entity 146423 ConversionCommon Stock 625,482 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-051838 · doc4.xml · nonDerivative · entry 1

Sofinnova Venture Partners VIII, L.P. · CIK 0001524064 · 10% owner

Sofinnova Management VIII, L.L.C. · CIK 0001559565 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 625,482

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Series B-1 Preferred Stock converted immediately upon the closing of the Issuer's initial public offering of its common stock into 1 share of the Issuer's common stock.

F2 · ownership.direct: The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SM VIII are Michael Powell, James Healy and Anand Mehra, and they may be deemed to share voting and dispositive power over the shares held by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares held by SVP VIII except to the extent of any pecuniary interest therein.

Read SEC document
June 13, 2018 Filed Jun 14, 2018 20:05 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $9.36 $0.00
Disclosure

SEC source: 0000899243-18-016591 · doc4.xml · derivative · entry 1

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2028-06-13

F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to the reporting person's continued service as a director of the Corporation.

Read SEC document
May 30, 2018 Filed May 30, 2018 21:59 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionSeries B-2 Preferred Shares · Derivative 229,660 $0.00 $0.00
Disclosure

SEC source: 0001144204-18-031803 · tv495514_form4.xml · derivative · entry 7

Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 229,660 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F4 · derivative.exercise_date: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F5 · derivative.expiration_date: Not applicable.

F2 · ownership.direct: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any.

Read SEC document
May 30, 2018 Filed May 30, 2018 21:59 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionSeries B-1 Preferred Shares · Derivative 275,446 $0.00 $0.00
Disclosure

SEC source: 0001144204-18-031803 · tv495514_form4.xml · derivative · entry 6

Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 275,446 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F3 · derivative.exercise_date: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F5 · derivative.expiration_date: Not applicable.

F2 · ownership.direct: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any.

Read SEC document
May 30, 2018 Filed May 30, 2018 21:59 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionSeries A Preferred Shares · Derivative 721,408 $0.00 $0.00
Disclosure

SEC source: 0001144204-18-031803 · tv495514_form4.xml · derivative · entry 5

Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 721,408 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F1 · derivative.exercise_date: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F5 · derivative.expiration_date: Not applicable.

F2 · ownership.direct: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any.

Read SEC document
May 30, 2018 Filed May 30, 2018 21:59 UTC Iterum Therapeutics plc ITRM · Entity 72802 PurchaseOrdinary Shares 500,000 $13.00 $6,500,000.00
Disclosure

SEC source: 0001144204-18-031803 · tv495514_form4.xml · nonDerivative · entry 4

Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,726,514

F2 · ownership.direct: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any.

Read SEC document
May 30, 2018 Filed May 30, 2018 21:59 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionOrdinary Shares 229,660 Not disclosed Not disclosed
Disclosure

SEC source: 0001144204-18-031803 · tv495514_form4.xml · nonDerivative · entry 3

Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,226,514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F2 · ownership.direct: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any.

Read SEC document
May 30, 2018 Filed May 30, 2018 21:59 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionOrdinary Shares 275,446 Not disclosed Not disclosed
Disclosure

SEC source: 0001144204-18-031803 · tv495514_form4.xml · nonDerivative · entry 2

Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 996,854

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F2 · ownership.direct: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any.

Read SEC document
May 30, 2018 Filed May 30, 2018 21:59 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionOrdinary Shares 721,408 Not disclosed Not disclosed
Disclosure

SEC source: 0001144204-18-031803 · tv495514_form4.xml · nonDerivative · entry 1

Sofinnova Venture Partners IX, L.P. · CIK 0001612133 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Sofinnova Management IX, L.L.C. · CIK 0001612134 · 10% owner

Mehra Anand · CIK 0001590102 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 721,408

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F2 · ownership.direct: These shares are held directly by Sofinnova Venture Partners IX, L.P. (the "Fund"). The general partner of the Fund is Sofinnova Management IX, L.L.C. (the "GP") and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Fund. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of the GP and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by the Fund. Each of the reporting persons disclaims beneficial ownership of such shares, except to the extent of his, her or its proportionate pecuniary interest therein, if any.

Read SEC document
January 26, 2018 Filed Jan 30, 2018 21:30 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantCommon Stock 150,000 $9.75 $1,462,500.00
Disclosure

SEC source: 0000899243-18-002261 · doc4.xml · nonDerivative · entry 1

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 574,972

F1 · ownership.nature: The shares are held by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The individual managing members of SVP VIII are Michael Powell, James Healy and Anand Mehra. The managing members share voting and dispositive power with regard to the shares held directly by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares owned by SVP VIII except to the extent of any pecuniary interest therein.

Read SEC document
December 29, 2017 Filed Jan 3, 2018 21:31 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 18,572 $0.00 Strike: $9.70 $0.00
Disclosure

SEC source: 0000899243-18-000275 · doc4.xml · derivative · entry 1

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,572

Underlying: Common Stock · 18,572 shares

Expires 2027-12-29

F1 · derivative.exercise_date: The options vest and become exercisable in substantially equal installments on each of the first three anniversaries of August 28, 2017 subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date.

Read SEC document
August 28, 2017 Filed Aug 30, 2017 20:06 UTC SYNLOGIC, INC. SYBX · Entity 7801 GrantStock Option (right to buy) · Derivative 1,428 $0.00 Strike: $12.07 $0.00
Disclosure

SEC source: 0000899243-17-021254 · doc4.xml · derivative · entry 1

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,428

Underlying: Common Stock · 1,428 shares

Expires 2027-08-28

F1 · derivative.exercise_date: The option vests and become exercisable in full on the earlier of (A) August 28, 2018 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

Read SEC document
October 31, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 OtherCommon Stock 14,328 $0.00 $0.00
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · nonDerivative · entry 10

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 14,328

F10 · acquired: Shares acquired by SV LLC in connection with the distributions reported above.

F11 · ownership.nature: Shares are held by SV LLC. SV LLC is the general partner of each of SV VI, SV KG, and SV A, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
October 31, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 OtherCommon Stock 9,540 $0.00 $0.00
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · nonDerivative · entry 9

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F9 · acquired: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by SV A without consideration to its partners.

F3 · ownership.nature: Shares are held by Sofinnova Venture Affiliates VI, L.P. ("SV A"). SV LLC is the general partner of SV A, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
October 31, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 OtherCommon Stock 138,686 $0.00 $0.00
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · nonDerivative · entry 8

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F8 · acquired: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by SV KG without consideration to its partners.

F2 · ownership.nature: Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG ("SV KG"). SV LLC is the managing limited partner of SV KG, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
October 31, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 OtherCommon Stock 699,996 $0.00 $0.00
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · nonDerivative · entry 7

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F7 · acquired: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by SV VI without consideration to its partners.

F1 · ownership.nature: Shares are held by Sofinnova Venture Partners VI, L.P. ("SV VI"). Sofinnova Management VI, L.L.C. ("SV LLC") is the general partner of SV VI and Michael F. Powell ("Powell"), a director of the Issuer, James I. Healy ("Healy"), Alain L. Azan ("Azan") and Eric P. Buatois ("Buatois"), the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
October 20, 2016 Filed Oct 24, 2016 16:49 UTC MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 SaleCommon Stock 12,528 $1.39 $17,401.39
Disclosure

SEC source: 0001144204-16-129201 · v450997_4.xml · nonDerivative · entry 3

Mehra Anand · CIK 0001590102 · 10% owner

SOFINNOVA VENTURE PARTNERS VI L P · CIK 0001211465 · 10% owner

Sofinnova Venture Partners VI GmbH & Co. KG · CIK 0001397189 · 10% owner

Sofinnova Venture Affiliates VI LP · CIK 0001312272 · 10% owner

Sofinnova Management VI, L.L.C. · CIK 0001397188 · 10% owner

Buatois Eric · CIK 0001362314 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

Azan Alain · CIK 0001294340 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 15,470

F3 · ownership.nature: Shares are held by Sofinnova Venture Affiliates VI, L.P. ("SVA VI"). SM VI is the general partner of SVA VI, and Healy, Powell, Azan and Buatois, the managing members of SM VI, and Mehra, a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
October 20, 2016 Filed Oct 24, 2016 16:49 UTC MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 SaleCommon Stock 13,367 $1.39 $18,566.76
Disclosure

SEC source: 0001144204-16-129201 · v450997_4.xml · nonDerivative · entry 2

Mehra Anand · CIK 0001590102 · 10% owner

SOFINNOVA VENTURE PARTNERS VI L P · CIK 0001211465 · 10% owner

Sofinnova Venture Partners VI GmbH & Co. KG · CIK 0001397189 · 10% owner

Sofinnova Venture Affiliates VI LP · CIK 0001312272 · 10% owner

Sofinnova Management VI, L.L.C. · CIK 0001397188 · 10% owner

Buatois Eric · CIK 0001362314 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

Azan Alain · CIK 0001294340 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 224,845

F2 · ownership.nature: Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG ("SVP KG"). SM VI is the managing limited partner of SVP KG, and Healy, Powell, Azan and Buatois, the managing members of SM VI, and Mehra, a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
October 20, 2016 Filed Oct 24, 2016 16:49 UTC MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 SaleCommon Stock 724,788 $1.39 $1,006,730.53
Disclosure

SEC source: 0001144204-16-129201 · v450997_4.xml · nonDerivative · entry 1

Mehra Anand · CIK 0001590102 · 10% owner

SOFINNOVA VENTURE PARTNERS VI L P · CIK 0001211465 · 10% owner

Sofinnova Venture Partners VI GmbH & Co. KG · CIK 0001397189 · 10% owner

Sofinnova Venture Affiliates VI LP · CIK 0001312272 · 10% owner

Sofinnova Management VI, L.L.C. · CIK 0001397188 · 10% owner

Buatois Eric · CIK 0001362314 · 10% owner

HEALY JAMES · CIK 0001245624 · 10% owner

Azan Alain · CIK 0001294340 · 10% owner

POWELL MICHAEL · CIK 0001202793 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,134,851

F1 · ownership.nature: Shares are held by Sofinnova Venture Partners VI, L.P. ("SVP VI"). Sofinnova Management VI, L.L.C. ("SM VI") is the general partner of SVP VI and James I. Healy ("Healy"), Michael F. Powell ("Powell"), Alain L. Azan ("Azan") and Eric P. Buatois ("Buatois"), the managing members of SM VI, and Anand Mehra ("Mehra"), a former director of the Issuer, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
September 12, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 OtherStock warrant (right to buy) · Derivative 125 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · derivative · entry 16

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 125 shares

Expires 2019-10-01

F3 · ownership.nature: Shares are held by Sofinnova Venture Affiliates VI, L.P. ("SV A"). SV LLC is the general partner of SV A, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
September 12, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 OtherStock warrant (right to buy) · Derivative 125 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · derivative · entry 15

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 125 shares

Expires 2012-03-30

F3 · ownership.nature: Shares are held by Sofinnova Venture Affiliates VI, L.P. ("SV A"). SV LLC is the general partner of SV A, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
September 12, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 OtherStock warrant (right to buy) · Derivative 1,820 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · derivative · entry 14

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,820 shares

Expires 2019-10-01

F2 · ownership.nature: Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG ("SV KG"). SV LLC is the managing limited partner of SV KG, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
September 12, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 OtherStock warrant (right to buy) · Derivative 1,820 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · derivative · entry 13

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,820 shares

Expires 2019-03-30

F2 · ownership.nature: Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG ("SV KG"). SV LLC is the managing limited partner of SV KG, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
September 12, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 OtherStock warrant (right to buy) · Derivative 9,187 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · derivative · entry 12

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 9,187 shares

Expires 2019-10-01

F1 · ownership.nature: Shares are held by Sofinnova Venture Partners VI, L.P. ("SV VI"). Sofinnova Management VI, L.L.C. ("SV LLC") is the general partner of SV VI and Michael F. Powell ("Powell"), a director of the Issuer, James I. Healy ("Healy"), Alain L. Azan ("Azan") and Eric P. Buatois ("Buatois"), the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
September 12, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 OtherStock warrant (right to buy) · Derivative 9,187 $0.00 Strike: $0.67 $0.00
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · derivative · entry 11

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 9,187 shares

Expires 2019-03-30

F1 · ownership.nature: Shares are held by Sofinnova Venture Partners VI, L.P. ("SV VI"). Sofinnova Management VI, L.L.C. ("SV LLC") is the general partner of SV VI and Michael F. Powell ("Powell"), a director of the Issuer, James I. Healy ("Healy"), Alain L. Azan ("Azan") and Eric P. Buatois ("Buatois"), the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
September 12, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 SaleCommon Stock 74 $2.29 $169.61
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · nonDerivative · entry 6

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 9,540

F6 · acquired: On September 12, 2016, the holder exercised warrants to purchase 250 shares of OCRX common stock for $0.67 a share. The holder paid the exercise price on a cashless basis, resulting in OCRX's withholding of 74 of the warrant shares to pay the exercise price and issuing to the holder the remaining 176 shares.

F3 · ownership.nature: Shares are held by Sofinnova Venture Affiliates VI, L.P. ("SV A"). SV LLC is the general partner of SV A, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
September 12, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 SaleCommon Stock 1,066 $2.29 $2,443.27
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · nonDerivative · entry 5

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 138,686

F5 · acquired: On September 12, 2016, the holder exercised warrants to purchase 3,640 shares of OCRX common stock for $0.67 a share. The holder paid the exercise price on a cashless basis, resulting in OCRX's withholding of 1,066 of the warrant shares to pay the exercise price and issuing to the holder the remaining 2,574 shares.

F2 · ownership.nature: Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG ("SV KG"). SV LLC is the managing limited partner of SV KG, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
September 12, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 SaleCommon Stock 5,372 $2.29 $12,312.62
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · nonDerivative · entry 4

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 699,996

F4 · acquired: On September 12, 2016, the holder exercised warrants to purchase 18,374 shares of OCRX common stock for $0.67 a share. The holder paid the exercise price on a cashless basis, resulting in OCRX's withholding of 5,372 of the warrant shares to pay the exercise price and issuing to the holder the remaining 13,002 shares.

F1 · ownership.nature: Shares are held by Sofinnova Venture Partners VI, L.P. ("SV VI"). Sofinnova Management VI, L.L.C. ("SV LLC") is the general partner of SV VI and Michael F. Powell ("Powell"), a director of the Issuer, James I. Healy ("Healy"), Alain L. Azan ("Azan") and Eric P. Buatois ("Buatois"), the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
September 12, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 OtherCommon Stock 250 $0.67 $167.50
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · nonDerivative · entry 3

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 9,614

F3 · ownership.nature: Shares are held by Sofinnova Venture Affiliates VI, L.P. ("SV A"). SV LLC is the general partner of SV A, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
September 12, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 OtherCommon Stock 3,640 $0.67 $2,438.80
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · nonDerivative · entry 2

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 139,752

F2 · ownership.nature: Shares are held by Sofinnova Venture Partners VI GmbH & Co. KG ("SV KG"). SV LLC is the managing limited partner of SV KG, and Healy, Powell, Azan and Buatois, the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
September 12, 2016 Filed Dec 30, 2016 18:51 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 OtherCommon Stock 18,374 $0.67 $12,310.58
Disclosure

SEC source: 0001144204-16-141985 · v455976_form4.xml · nonDerivative · entry 1

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 705,368

F1 · ownership.nature: Shares are held by Sofinnova Venture Partners VI, L.P. ("SV VI"). Sofinnova Management VI, L.L.C. ("SV LLC") is the general partner of SV VI and Michael F. Powell ("Powell"), a director of the Issuer, James I. Healy ("Healy"), Alain L. Azan ("Azan") and Eric P. Buatois ("Buatois"), the managing members of SV LLC, may be deemed to share voting and dispositive power over the shares held by such entities.

Read SEC document
July 29, 2016 Filed Feb 10, 2017 16:09 UTC Ocera Therapeutics, Inc. OCRX · Entity 171193 SaleCommon Stock 11,969 $2.53 $30,281.57
Disclosure

SEC source: 0001274644-17-000005 · wf-form5_148676095579836.xml · nonDerivative · entry 1

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: These shares were issued upon the Reporting Person's exercise of a stock option on July 11, 2016 that was reported on a Form 4 filed on July 13, 2016. The cash proceeds from this sale of the shares were donated by the Reporting Person to Washington University in St. Louis on August 17, 2016.

F1 · shares: These shares were issued upon the Reporting Person's exercise of a stock option on July 11, 2016 that was reported on a Form 4 filed on July 13, 2016. The cash proceeds from this sale of the shares were donated by the Reporting Person to Washington University in St. Louis on August 17, 2016.

Read SEC document
June 29, 2016 Filed Sep 6, 2016 22:29 UTC SYNLOGIC, INC. MIRN · Entity 7801 GrantStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $4.74 $0.00
Disclosure

SEC source: 0001140361-16-078998 · doc1.xml · derivative · entry 1

POWELL MICHAEL · CIK 0001202793 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2026-06-29

F1 · derivative.exercise_date: The option vests and become exercisable in full on the earlier of (A) June 29, 2017 or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.